Trevi Therapeutics, Inc. (TRVI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US89532M1018
Trevi Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -49.33 m USD |
| EBIT | -49.36 m USD |
| Net income | -42.76 m USD |
| Diluted EPS – continuing operations | -0.32 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
More stocks
- Zhejiang Yongtai Technology Co Ltd (002326.SZ)
- Embracer Group AB (EMBRAC B.ST)
- Baoding Heavy Industry Co Ltd (002552.SZ)
- Louis Hachette Group SA (ALHG.PA)
- Wuhu Token Sciences (300088.SZ)
- MIXUE Group (MXUBY)
- Teijin Ltd (3401.T)
- Xi'an Sinofuse Electric Co. Ltd. (301031.SZ)
- Globant SA (GLOB)
- FERRELLGAS PARTNERS L P (FGPR)
- PERDOCEO EDUCATION Corp (PRDO)
- Malaysian Pacific Industries (3867.KL)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.